Brief: Adaptive Biotechnologies Announces Translational Collaboration With Takeda To Measure Minimal Residual Disease With Its Clonoseq Assay Across Its Hematologic Malignancy Pipeline

Adaptive Biotechnologies

12/04/2023 13:55

April 12 (Reuters) - Adaptive Biotechnologies Corp
 ADPT.O :
    * ADAPTIVE BIOTECHNOLOGIES ANNOUNCES TRANSLATIONAL
COLLABORATION
WITH TAKEDA TO MEASURE MINIMAL RESIDUAL DISEASE WITH ITS
CLONOSEQ® ASSAY ACROSS ITS HEMATOLOGIC MALIGNANCY PIPELINE
    * ADAPTIVE BIOTECHNOLOGIES CORP - SPECIFIC FINANCIAL TERMS
OF
AGREEMENT WILL NOT BE DISCLOSED

Source text for Eikon:  ID:nGNX8y7dJn 
Further company coverage:  ADPT.O 

 ((Reuters.Briefs@thomsonreuters.com;;))